Effect of Minimally Invasive versus Open Distal Gastrectomy on Long-Term Survival in Patients with Gastric Cancer: Individual Patient Data Meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 4/4)
유사 논문P · Population 대상 환자/모집단
5297 patients) were included; 50.
I · Intervention 중재 / 시술
Effect of Minimally Invasive
C · Comparison 대조 / 비교
Open Distal Gastrectomy on Long
O · Outcome 결과 / 결론
The 36-month DFS appraisal for stage III patients (three studies) was - 0.41 months (95% CI - 26.1, 38.2; low level of certainty). [CONCLUSIONS] This meta-analysis found high-certainty evidence that MIDG and ODG demonstrate similar 5-year OS and DFS in patients with both EGC and LAGC.
[BACKGROUND] Minimally invasive distal gastrectomy (MIDG) has been shown to improve short-term outcomes compared with open distal gastrectomy (ODG) in patients with early (EGC) and locally advanced ga
- 연구 설계 meta-analysis
APA
Calì M, Bona D, et al. (2025). Effect of Minimally Invasive versus Open Distal Gastrectomy on Long-Term Survival in Patients with Gastric Cancer: Individual Patient Data Meta-analysis.. Annals of surgical oncology, 32(3), 2161-2171. https://doi.org/10.1245/s10434-024-16677-9
MLA
Calì M, et al.. "Effect of Minimally Invasive versus Open Distal Gastrectomy on Long-Term Survival in Patients with Gastric Cancer: Individual Patient Data Meta-analysis.." Annals of surgical oncology, vol. 32, no. 3, 2025, pp. 2161-2171.
PMID
39676114
Abstract
[BACKGROUND] Minimally invasive distal gastrectomy (MIDG) has been shown to improve short-term outcomes compared with open distal gastrectomy (ODG) in patients with early (EGC) and locally advanced gastric cancer (LAGC). The impact of MIDG on patient survival remains debated. This study aimed to compare the effect of MIDG versus ODG on long-term survival.
[PATIENTS AND METHODS] Randomized clinical trial (RCTs) individual patient data (IPD) meta-analysis with restricted mean survival time difference (RMSTD) estimation. Scopus, MEDLINE, Web of Science, and ClinicalTrials.gov were searched. Primary outcomes were 5-year overall (OS), disease free survival (DFS), and cancer specific survival (CSS). RMSTD and 95% confidence intervals (CI) were used as pooled effect size measures. The certainty of evidence was categorized with the Grading of Recommendations, Assessment, Development, and Evaluation framework.
[RESULTS] Overall, ten RCTs (5297 patients) were included; 50.4% of patients underwent MIDG. At 60-months follow-up, the OS and DFS estimates for ODG versus MIDG were 0.41 months (95% CI - 0.17, 0.99; high level of certainty) and 0.42 months (95% CI - 0.38, 1.23; high level of certainty). CSS was specified in two RCTs, hence quantitative analysis was not practicable. The 60-month OS and DFS estimates for LAGC (five studies) were 0.32 months (95% CI - 0.80, 1.44; high level of certainty) and 0.31 months (95% CI - 2.02, 1.33; high level of certainty), respectively. The 36-month DFS appraisal for stage III patients (three studies) was - 0.41 months (95% CI - 26.1, 38.2; low level of certainty).
[CONCLUSIONS] This meta-analysis found high-certainty evidence that MIDG and ODG demonstrate similar 5-year OS and DFS in patients with both EGC and LAGC.
[PATIENTS AND METHODS] Randomized clinical trial (RCTs) individual patient data (IPD) meta-analysis with restricted mean survival time difference (RMSTD) estimation. Scopus, MEDLINE, Web of Science, and ClinicalTrials.gov were searched. Primary outcomes were 5-year overall (OS), disease free survival (DFS), and cancer specific survival (CSS). RMSTD and 95% confidence intervals (CI) were used as pooled effect size measures. The certainty of evidence was categorized with the Grading of Recommendations, Assessment, Development, and Evaluation framework.
[RESULTS] Overall, ten RCTs (5297 patients) were included; 50.4% of patients underwent MIDG. At 60-months follow-up, the OS and DFS estimates for ODG versus MIDG were 0.41 months (95% CI - 0.17, 0.99; high level of certainty) and 0.42 months (95% CI - 0.38, 1.23; high level of certainty). CSS was specified in two RCTs, hence quantitative analysis was not practicable. The 60-month OS and DFS estimates for LAGC (five studies) were 0.32 months (95% CI - 0.80, 1.44; high level of certainty) and 0.31 months (95% CI - 2.02, 1.33; high level of certainty), respectively. The 36-month DFS appraisal for stage III patients (three studies) was - 0.41 months (95% CI - 26.1, 38.2; low level of certainty).
[CONCLUSIONS] This meta-analysis found high-certainty evidence that MIDG and ODG demonstrate similar 5-year OS and DFS in patients with both EGC and LAGC.
MeSH Terms
Humans; Stomach Neoplasms; Gastrectomy; Survival Rate; Minimally Invasive Surgical Procedures; Randomized Controlled Trials as Topic; Prognosis